parkinson’s disease
Emil Chuang, Chief Medical Officer at Intrinsic Medicine, explores the growing understanding of gut-brain axis disorders and the potential of Human Milk Oligosaccharides (HMOs) in their treatment.
The study seeks to identify specific microbial and metabolic markers in the small intestinal fluid and blood of PD patients, offering new avenues for therapeutic intervention.
Metabolon and the Oxford Parkinson's Disease Centre will identify new metabolomic biomarkers to advance Parkinson's research and detect new therapeutic targets
The alterations in gut microbial composition could play a role in the gastrointestinal complications associated with Parkinson’s disease.
A japanese team identified bacterial populations that may determine intestinal pathology and influence the development of Parkinson's disease.
Researchers have found that lung bacteria could help to predict how well people in intensive care will respond to treatment.
A new study published in Cell Reports suggests that a common gut microbe could slow—and even reverse—the build-up of a protein associated with Parkinson's.
Specific gut bacteria break down levodopa, which is used to treat Parkinson’s. This could lead to the development of new levodopa therapies.
